Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) has been assigned an average rating of “Buy” from the seventeen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $56.00.
SRRK has been the subject of several research analyst reports. HC Wainwright increased their price objective on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. JPMorgan Chase & Co. increased their price objective on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 16th. Canaccord Genuity Group initiated coverage on Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price objective for the company. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Finally, Piper Sandler increased their price objective on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th.
View Our Latest Analysis on SRRK
Insider Transactions at Scholar Rock
Institutional Investors Weigh In On Scholar Rock
Several hedge funds have recently modified their holdings of SRRK. AQR Capital Management LLC lifted its holdings in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the period. Millennium Management LLC lifted its holdings in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after purchasing an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares during the period. Finally, Strs Ohio acquired a new stake in shares of Scholar Rock during the first quarter worth $77,000. 91.08% of the stock is owned by institutional investors and hedge funds.
Scholar Rock Stock Performance
Shares of Scholar Rock stock opened at $44.18 on Friday. The firm has a market capitalization of $5.29 billion, a P/E ratio of -12.31 and a beta of 0.69. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $52.19. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The firm’s 50 day moving average is $47.88 and its two-hundred day moving average is $45.82.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter last year, the business earned ($0.67) earnings per share. Research analysts forecast that Scholar Rock will post -3.23 EPS for the current fiscal year.
Scholar Rock Company Profile
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Read More
- Five stocks we like better than Scholar Rock
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
- TJX: Retail’s Apex Predator Feasts on Inflation
- MarketBeat Week in Review – 06/08 – 06/12
- SpaceX Rings the Bell and Shatters Every Record
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
